School of Medicine
Showing 551-600 of 1,054 Results
-
Anne Liu
Clinical Associate Professor, Pediatrics - Immunology and Allergy
Clinical Associate Professor (By courtesy), Medicine - Pulmonary, Allergy & Critical Care MedicineBioDr. Liu is a board-certified, fellowship-trained specialist in allergy/immunology and infectious disease. She is also a clinical associate professor in the Department of Medicine, Division of Infectious Diseases and the Department of Pediatrics, Division of Allergy, Immunology, and Rheumatology at Stanford University School of Medicine.
Dr. Liu treats infections in patients with compromised immune systems, whether due to a primary immune deficiency or a condition like cancer or organ transplant. She helps patients to develop tolerance to medications they are allergic to so that they can receive the best, and sometimes the only, treatments available to them. She also treats allergies to antibiotics, aspirin, NSAIDs, chemotherapy, and more. She sees patients both long term and for urgent referrals, such as in cases of perioperative anaphylaxis. Dr. Liu also helps pediatric patients manage drug and food allergies.
One of Dr. Liu’s areas of focus is helping patients with allergies to antibiotics determine when they have lost an allergy, what antibiotics they can tolerate, and when to induce tolerance to an antibiotic. This not only can benefit the patient, but also have a positive public health impact, as labeling patients with a penicillin allergy may negatively affect their care and increase use
of broad-spectrum antibiotics.
She collaborates closely with colleagues from other disciplines, including pulmonology, otolaryngology, oncology, cardiology, dermatology, anesthesiology, and surgery. Her key objective in working with referring physicians is to help them safely deliver the best care for their patients.
For patients and families, Dr. Liu strives to help them navigate their care journey with as much ease and dignity as possible during what may be the most challenging time of their life. Her goal is to offer patients options, even when it may appear that they have no options left.
Dr. Liu’s research interests include optimizing care of patients with antibiotic allergies, including through use of decision support tools.
Dr. Liu has authored articles in the New England Journal of Medicine, Journal of Immunology, Journal of Allergy and Clinical Immunology in Practice, Clinical and Experimental Allergy, Mucosal Immunology, Diagnostic Microbiology and Infectious Disease, Science, and other publications. Dr. Liu authored the book chapter “Hypersensitivity Reactions to Monoclonal Antibodies” in Drug Allergy Testing.
Dr. Liu is certified in infectious disease by the American Board of Internal Medicine and in allergy and immunology by the American Board of Allergy and Immunology. She is also a member of the American College of Physicians, Infectious Diseases Society of America, and American Academy of Allergy, Asthma, and Immunology.
She has given presentations on antibiotic allergies, drug desensitization, and aspirin-exacerbated respiratory disease, among other topics. Dr. Liu’s honors include recognition from the American Academy of Asthma, Allergy, and Immunology, the American Medical Women’s Association, and the National Institutes of Health. -
Christine Kee Liu
Assistant Professor of Medicine (Primary Care and Population Health)
BioDr. Liu and her research program are dedicated to improving the lives of older adults with kidney disease. Currently her research focuses on mobility, which is the ability to move safely and reliably from one place to another. In older adults, poor mobility strongly predicts future disability and death. Retaining mobility has been cited by older adults as fundamental to quality to life; yet many older persons with kidney disease, especially those with late stage chronic kidney disease or outright kidney failure, have trouble just walking across the room or transferring to a chair. Dually trained in geriatric medicine and epidemiology, Dr. Liu also has significant expertise in older adult clinical trials, including safety trials of novel agents as well as intervention studies to reduce infections in older populations.
-
Nathan Lo
Assistant Professor of Medicine (Infectious Diseases)
Current Research and Scholarly InterestsOur research laboratory is interested in studying the transmission of infectious diseases and impact of public health interventions with an ultimate goal of informing public health policy. We study a diverse set of pathogens, both domestically and internationally, including vaccine-preventable infections (including COVID-19) and neglected parasitic diseases (such as schistosomiasis). Our group applies diverse computational methodologies, including tools from fields of epidemiology, mathematical and statistical modeling, simulation, and policy analysis.
A large emphasis of our work is translating scientific evidence into public health policy. Our track record includes multiple studies that have changed policy in the fields of neglected parasitic diseases and COVID-19. We work closely with policy organizations like the World Health Organization and the California Department of Public Health. Nathan served as the lead writer of the World Health Organization guidelines on schistosomiasis (2022) and strongyloidiasis (2024).
Our current research focuses on the following areas:
(1) Vaccine-preventable infectious diseases (including COVID-19) in the United States, with a focus on studying vaccines and transmission dynamics
(2) Public health strategies for control and elimination of globally important neglected infectious diseases, such as helminths infections (schistosomiasis, strongyloidiasis) and typhoid fever
Hiring
We are seeking to fill multiple research positions at all levels. Candidates interested in working on computational public health research related to infectious diseases with a strong quantitative background are highly encouraged to apply. If you an interested, please submit a cover letter, CV, and names of two references to Nathan.Lo@stanford.edu. -
Karl Lorenz
Professor of Medicine (Primary Care and Population Health)
BioDr. Karl Lorenz, MD MSHS is a general internal medicine and palliative care physician, and Section chief of the VA Palo Alto-Stanford Palliative Care Program. Formerly at the VA Greater Los Angeles, Dr. Lorenz directed palliative care research at the VA Center for Innovation to Implementation and served on the faculty at the UCLA School of Medicine. Dr. Lorenz is a member of the VA’s national Hospice and Palliative Care Program (HPC) leadership team, director of the operational palliative care Quality Improvement Resource Center (QuIRC), and adjunct facility staff member at RAND. Dr. Lorenz’s work and leadership has been influential to the field of palliative care research. Under Dr. Lorenz’s leadership, since 2009 the Quality Improvement Resource Center (QuIRC) has served as one of three national leadership Centers responsible for strategic and operational support of the VA’s national hospice and palliative care programs. QuIRC develops and implements provider facing electronic tools for the VA’s national electronic medical record to improve the quality of palliative care. In that role, Dr. Lorenz participates with the national leadership team in strategic planning, policy development, and providing resources to support operational efforts. Dr. Lorenz has contributed to the field of global palliative care, serving the World Health Organization in its development of Palliative Care for Older People and leading methods for Palliative Care Essential Medications.
-
Kate Lorig
Professor (Research) of Medicine (Immunology and Rheumatology), Emerita
Current Research and Scholarly InterestsCommunity based psycoeducational intervention studies of disease self management for people with chronic diseases. arthritis, lung diseases, heart disease AIDs, low back pain and diabetes. Programs and studies in Spanish and English. Interventions are in small groups, mailed or on the Internet.
-
Anson Lowe
Associate Professor of Medicine (Gastroenterology and Hepatology), Emeritus
Current Research and Scholarly InterestsThe laboratory is focused on the relationship between injury, wound healing, and cancer. Esophageal, gastric, and pancreatic cancers are a focus. We are particularly interested in the regulation of cell signaling by EGFR, the EGF receptor. In addition to cancer pathogenesis, active projects include the development of new diagnostic assays and drugs.
-
Henry J. Lowe, MD
Associate Professor of Medicine (General Medical Disciplines) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsMy research in the field of biomedical informatics over the past 30 years has focused on the development of novel uses of information technology and computer science to improve human health. My current interests include the Electronic Health Record (EHR), biomedical knowledge representation, Internet applications in healthcare, clinical data warehouses, clinical data and text mining, academic social networking and the use of information technology to support clinical and translational research.
-
Robert Lowsky
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsDr. Lowsky's research is focused on understanding the role of regulatory T cells in the prevention of GVHD and in promoting immune tolerance following organ transplantation.
-
Sydney X. Lu
Assistant Professor of Medicine (Hematology)
BioSydney Lu is a hematologist and medical oncologist in the Division of Hematology, Department of Medicine, studying novel therapeutics for challenging cancers and immune disorders.
Sydney's research career started with graduate studies in the laboratory of Dr. Marcel van den Brink at Memorial Sloan Kettering Cancer Center (MSKCC) studying the biology of pathologic donor T cells during graft-versus-host-disease and beneficial T cells mediating graft-versus-tumor effects after allogeneic bone marrow transplant, as well as the role of the thymus in regenerating healthy and protective donor-derived T cells post-transplant.
The direct relevance of these cellular therapies and their immediate translational applicability to patients inspired him to attend medical school at Stanford and further training in hematology and medical oncology at Memorial Sloan Kettering. There, as a fellow and junior faculty member, he studied disordered RNA splicing in cancer in the laboratory of Dr. Omar Abdel-Wahab, with the goal of developing novel drugs targeting RNA splicing. This work has led to observations that targeted degradation of the RNA binding protein RBM39 may be a feasible therapeutic for the treatment of myeloid cancers bearing RNA splicing factor mutations and that pharmacologic RNA splicing inhibition can generate MHC I-presented peptide neoantigens which are exploitable for immunotherapy in model systems.
Sydney's laboratory is broadly interested in studying RNA processing and splicing in the contexts of:
1) normal and pathologic immunity and immunotherapy
2) cancer biology
3) normal and malignant hematopoiesis -
Stephen Luby
Lucy Becker Professor of Medicine, Senior Fellow at the Woods Institute for the Environment, Freeman Spogli Institute for International Studies and Professor, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsDr. Luby’s research interests include identifying and interrupting pathways of infectious disease transmission in low income countries.
-
George Lui
Clinical Professor, Medicine - Cardiovascular Medicine
Clinical Professor, Pediatrics - CardiologyCurrent Research and Scholarly InterestsAdult Congenital Heart Disease
-
Mitchell R. Lunn
Associate Professor of Medicine (Nephrology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsLGBTQIA+ health
-
Kevin M Lutley
Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioDr. Lutley is a primary care doctor. He is board certified in internal medicine.
For every patient, he creates a customized care plan. Plans focus on helping each person enjoy the best possible health and wellness.
Dr. Lutley has helped advance care through research. He has shared his research discoveries with his peers in invited presentations. Topics include drug prices in community pharmacies and the quality of interactions between patients and resident physicians.
While an internal medicine resident at Stanford, Dr. Lutley served as a member of the Stanford Ambulatory Care Excellence Program. This initiative aims to enhance the quality of outpatient primary care.
Dr. Lutley helps educate the primary care doctors of tomorrow. He is a clinical assistant professor of primary care and population health in the Stanford Department of Medicine, Division of Primary Care.
Before joining Stanford, Dr. Lutley performed needs assessments and care coordination with local public health agencies in Flint, Michigan.
Recognition for his achievements includes induction in the Gold Humanism Honor Society. This national organization honors senior medical students, residents, teachers and others for excellence in clinical care, leadership, and compassion. Additional honors for Dr. Lutley include induction in Alpha Omega Alpha, the honor society in the field of medicine.
From Stanford University, he received the Julian Wolfsohn Award. This honor goes to residents who demonstrate exemplary professionalism, teaching, and dedication to patient care.
Dr. Lutley is a member of the American College of Physicians. -
Crystal Mackall
Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine
Current Research and Scholarly InterestsRecent clinical studies, by us and others, have demonstrated that genetically engineered T cells can eradicate cancers resistant to all other therapies. We are identifying new targets for these therapeutics, exploring pathways of resistance to current cell therapies and creating next generation platforms to overcome therapeutic resistance. We have discovered novel insights into the biology of human T cell exhaustion and developed approaches to prevent and reverse this phenomenon.
-
David Magnus, Ph.D.
Thomas A. Raffin Professor of Medicine and Biomedical Ethics and Professor (Teaching) of Medicine (Primary Care and Population Health)
Current Research and Scholarly InterestsGenetic testing, gene therapy, genetically engineered organisms, and the history of eugenics. Stem cell research and cloning, and egg procurement. Examining ethical issues in reproductive technologies. Organ transplantation including donation after cardiac death, ethics of listing decisions. End of life issues in both adults and children.
-
Kenneth Mahaffey
Professor of Medicine (Cardiovascular Medicine)
BioClinical Focus: Cardiovascular Medicine: Atrial Fibrillation; Chronic CAD; ACS;
Research Focus:
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Associate Dean, Clinical Research School of Medicine; Vice Chair of Clinical Research Department of Medicine; Director Stanford Center for Clinical Research; Member of the Stanford IRB
Professional Training:
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Faculty Cardiovascular Medicine -
Anurag Mairal
Adjunct Professor, Medicine - Cardiovascular Medicine
BioDr. Anurag Mairal is an Adjunct Professor of Medicine and the Director, Global Outreach Programs at Stanford Byers Center for Biodesign, Stanford University. He is also a Faculty Fellow and Lead for Technology Innovation and Impact at Center for Innovation in Global Health. In these roles, he leads initiatives focused on applying the biodesign process to resource-constrained se ttings globally. Further, he facilitates opportunities for students, faculty and fellows at Stanford to work on global healthcare needs. He is founding co-Director for MED 232, Global Health: Scaling Health Technology Innovations in Low Resource Settings, and was part of the founding faculty team for BIOE 371, Global Biodesign: Medical Technology in an International Context, graduate-level courses offered to engineering, business, and medical students at Stanford University. Earlier, he served as Associate Director for the Stanford-India Biodesign and Singapore-Stanford Biodesign programs. He serves as the Founding Chair of BME IDEA APAC, a community of medtech innovation programs in Asia Pacific, partnering closely with the industry and academia in the region. He is also an Honorary Professor at University of Cape Town, South Africa. Concurrently, he is a co-founder and Executive Vice President of Orbees Medical, a SF Bay Area-based strategy consulting firm serving global healthcare industry, with a focus on medtech, pharmaceutical, and digital health industry.
Dr. Mairal has an extensive background in medical technology development and commercialization, collaborating with partners in the U.S., India, China, and other emerging markets to advance product development, manufacturing, and distribution. Recently, he took a sabbatical for two years to take a senior leadership role at PATH, a major global health nonprofit based in Seattle. In this role, he oversaw research and development, commercialization, and implementation of technologies in PATH’s medical devices, diagnostics, and digital health divisions. Previously, he held several positions at Johnson & Johnson, including Business Development Director and Product Director for structural heart, cardiology, and peripheral vascular products at Cordis. Before joining J&J, he was a Group Leader and a Process Development Manager at Membrane Technology and Research (MTR). At MTR, he was responsible for business development, strategic alliances, and product development in the bioseparations area. An active mentor to entrepreneurs and industry professionals, he serves as the chair of PATH’s Bay Area Leadership Council; chair of the board at EPPIC Global Network; chair of Faculty Alumni Network at IIT Bombay Heritage Foundation; and President of Sewa International - Bay Area.
Dr. Mairal earned a PhD in chemical engineering from the University of Colorado at Boulder and an MBA from the Haas School of Business at the University of California at Berkeley. He also holds an MS in chemical engineering from the Indian Institution of Technology in Mumbai and a BS in chemical engineering from National Institute of Technology, Raipur. Dr. Mairal was a post-doctoral fellow at the University of Twente, Netherlands and at University of Michigan, Ann Arbor. At BerkeleyHaas, he was a founding co-Chairman of the South Asia Business Conference and Chair of the Biotech Panel for the Asia Business Conference. His work has been published in more than 30 publications, and he has seven issued patents. -
Amrapali Maitra
Clinical Assistant Professor, Medicine
BioAmrapali Maitra is a clinician, educator, and scholar with training from Harvard and Stanford as well as a Paul and Daisy Soros Fellow for New Americans (2013). Her clinical practice emphasizes humanism and attention to health equity through structural competency. As an educator, she is committed to diversity and inclusion in the learning environment for pre-medical, medical, and graduate medical trainees, as well as centering patients as teachers. Her scholarship focuses on intimate partner violence, trauma-informed care, medical education, and the humanities.
-
Ravi Majeti MD, PhD
Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Virginia and D. K. Ludwig Professor and Professor of Medicine (Hematology)
Current Research and Scholarly InterestsThe Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for human hematopoietic cells.
-
Joshua Makower
Yock Family Professor and Professor of Bioengineering
Current Research and Scholarly InterestsDr. Josh Makower is the Boston Scientific Applied Bioengineering Professor of Medicine and of Bioengineering at the Stanford University Schools of Medicine and Engineering and the Director of the Stanford Byers Center for Biodesign, the program he co-founded with Dr. Paul Yock twenty years ago. Josh helped create the fundamental structure of the Center’s core curriculum and is the chief architect of what is now called “The Biodesign Process.” Over the past 20 years since Josh and Paul founded Biodesign, this curriculum and the associated textbook has been used at Stanford and across the world to train hundreds of thousands of students, faculty and industry leaders on the Biodesign process towards the advancement of medical innovation for the improvement of patient care. Josh has practiced these same techniques directly as the Founder & Executive Chairman of ExploraMed, a medical device incubator, creating 9 companies since 1995. Transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard & TransVascular, acquired by Medtronic. Other ExploraMed/NEA ventures include Moximed, NC8 and Willow. Josh is also a Special Partner at NEA where he supports the healthcare team and medtech/healthtech investing practice. Josh serves on the boards of Allay Therapeutics, Revelle Aesthetics, Setpoint Medical, DOTS Technologies, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow and Coravin. Josh holds over 300 patents and patent applications. He received an MBA from Columbia University, an MD from the NYU School of Medicine, a bachelor’s degree in Mechanical Engineering from MIT. Josh is a Member of the National Academy of Engineering and the College of Fellows of The American Institute for Medical and Biological Engineering and was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018.
-
Jose R. Maldonado, MD, FACLP, FACFE
John and Terry Levin Family Professor of Medicine and Professor, by courtesy, of Emergency Medicine and of Medicine
Current Research and Scholarly InterestsPathophysiology and Management of Delirium, Acute Brain Failure and Cognitive Impairment, Neuropsychiatric Sequelae of Traumatic Brain Injury, Factitious Disorder & Munchausen's Syndrome, Cultural Diversity in Medical Care, Psychiatric Complications of Bone Marrow Transplantation, Conversion Disorder, Depression in the Medically Ill, Neuropsychiatric Sequelae of Chronic Fatigue Syndrome.
-
Gabriel Mannis
Associate Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research focuses on the development of more effective, less toxic therapies for patients with AML and other high-risk hematologic malignancies. We study biologic correlates that predict response to therapy as well as factors/interventions that improve quality-of-life for patients struggling with blood-borne cancers.
-
Arek Melkon Manugian, MD
Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioDr. Manugian is a board-certified internal medicine doctor at Stanford Primary Care in Portola Valley. He is also a clinical assistant professor in the Division of Primary Care and Population Health in the Department of Medicine at Stanford University School of Medicine.
He has experience diagnosing, managing, and treating a wide range of conditions. These include gastrointestinal disorders, hypertension (high blood pressure), and obesity. Dr. Manugian develops an individualized care plan for each one of his patients.
Dr. Manugian’s research interests include blood pressure medication, gastric bypass surgery, and restless legs syndrome. He received a student research grant to study how the body processes glucagon (a hormone that regulates blood sugar) following gastric bypass surgery. Dr. Manugian has also studied muscle inflammation as a rare side effect of statins (drugs that lower cholesterol). He monitored a clinical trial evaluating the prescribing of drugs to lower high blood pressure. As a clinical research associate at the Stanford University Center for Sleep Sciences and Medicine, Dr. Manugian studied medications to treat restless legs syndrome.
Dr. Manugian presented research to his peers during his residency at the University of Cincinnati Medical Center. He has taught medical students, residents, and physicians about a variety of topics, including alcohol abuse, tick-born illnesses, and managing indigestion.
Dr. Manugian is a member of the American College of Physicians. -
Robert Marcus
Professor (Clinical) of Medicine (Endocrinology, Gerontology and Metabolism), Emeritus
Current Research and Scholarly InterestsI have been retired since 2008 and no longer conduct research
